-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Johnson and Johnson announced that Ad26.COV2.S, a candidate new crown vaccine developed by the company, has achieved new positive results in preclinical studies.
Data published today in Nature Medicine show that the new coronavirus serotype 26 (Ad26) vector, called Ad26.COV2.S, causes the production of mesothroid antibodies in Syrian golden hamsters and prevents serious clinical symptoms of neo-coronary pneumonia, including weight loss, pneumonia and death.
July, Johnson and Johnson published the Ad26.COV2.S vaccine in the journal Nature, which triggers an immune response in preclinical studies of non-human primates (NHPs).
Nature's study showed that Ad26.COV2.S needed only one inoculation, which not only stimulated a strong mesothetic antibody and cellular immune response in non-human primate models, but also achieved full or almost complete protection in subsequent drug tests on animals.
a recently published study in Nature, Johnson and Johnson continued to test the vaccine candidate in golden hamsters, which are often more likely than NHP to show symptoms of severe new coronavirus infections.
in this preclinical study, the researchers exempted gold hamsters from a single injection of the Ad26.COV2.S vaccine, which induced nalocation of antibodies in all vaccinated animals.
four weeks later, the animals were exposed to high doses of SARS-CoV-2 virus.
less weight and fewer viruses in their lungs and other organs than unvaccinated control animals, the study said.
animals that have been vaccinated have not died.
, the researchers found a negative correlation between the negative antibody response and weight loss and lung virus replication.
plans to begin Phase 3 trials this month and will continue to work to expand vaccine manufacturing capacity to ensure global supply after proven vaccine effectiveness.
.